(WASHINGTON, D.C.) – Consumer Healthcare Products Association (CHPA) President & CEO Scott Melville released the below statement today following President-elect Donald Trump’s recent nomination of Dr. Marty Makary to lead the U.S. Food and Drug Administration (FDA):
“CHPA welcomes the nomination of surgeon, public health researcher, and author Dr. Marty Makary to be the next FDA Commissioner. Dr. Makary has strong academic and medical credentials, made extensive contributions to scholarly and professional publications, and has stated his commitment to evidence-based medicine. CHPA specifically hopes this nomination will help further FDA's mission to protect and promote public health with more evidence-based self-care options for consumers. We look forward to learning more about Dr. Makary's positions and priorities on OTC drugs, dietary supplements, and OTC medical devices as he proceeds through the confirmation process.”
